Ardelyx Investor Relations Material

Ardelyx Inc is a biopharmaceutical company engaged in discovering, developing, and commercializing novel treatments for patients with gastrointestinal and cardiorenal diseases. Their approach focuses on creating targeted, first-in-class, oral, small molecule therapies that address significant unmet medical needs. The company's flagship product candidate is tenapanor, aimed at treating irritable bowel syndrome with constipation. Furthermore, Ardelyx is advancing XPHOZAH in Phase III clinical trials for controlling serum phosphorus in patients with chronic kidney disease on dialysis, and other product candidates like RDX013 and RDX020 target hyperkalemia and metabolic acidosis, respectively. Ardelyx has formed strategic partnerships with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in various territories. Originally founded as Nteryx, Inc., the company rebranded to Ardelyx, Inc. in 2008 and is headquartered in Waltham, Massachusetts, with its shares listed on the NASDAQ.